Future testing of CCL-2 and sFasL should therefore be conducted on a larger study cohort with more examples of discrete diagnostic categories; e.g. more examples of patients with steatosis but no inflammation might help to elucidate the use of CCL-2 as a biomarker, since CCL-2 has been speculated to play a role in the transition from simple steatosis to NASH [14]. This evidence concerns the gene CCL2 and metabolic dysfunction-associated steatohepatitis.